ClinicalTrials.gg
CompletedNCT07304427Updated Dec 26, 2025

Alwide Plus China Post-market Clinical Investigation

An observational study in Severe Aortic Stenosis and Transcatheter Aortic Valve Replacemen, sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd.. Completed at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd. (part of MicroPort Scientific Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Enrollment
20th of 22
75 · median 490
Started
2025
with 10 others
Observational
22 of 69
16 open now
Registered
57th of 69
by date
Lead sponsor
6 of 69
Shanghai MicroPort CardioFlow Medtech Co., Ltd.

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 20th largest by enrollment of the 22 observational ones that give a count, is one of 11 that started in 2025, is one of 22 observational ones, and was the 57th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

This is a prospective, single-arm, multi-center, post-market registry study conducted in China. The purpose is to evaluate the safety and effectiveness of the AlwideTM Plus balloon catheter for pre-dilatation of the aortic valve during TAVR in the real-world setting.

Read the detailed description

The study is designed to evaluate the safety and effectiveness of the Alwide Plus balloon catheter for pre-dilatation of the aortic valve during in transcatheter aortic valve replacement in the real-world setting, with TAVI device success at immediate post-procedure as the primary endpoint. The immediate post-procedural pre-dilation success, all-cause mortality, stroke, bleeding, acute kidney injury, permanent pacemaker implantation, major vascular complication, valve function at post-procedure and discharge, and post-dilation success will be used as secondary endpoints.This is a prospective, multi-center, post market clinical investigation. 75 patients will be enrolled in this clinical investigation. All subjects will undergo telephone follow-up at 30 days post-procedure.

03

Conditions studied

  • Severe Aortic Stenosis
  • Transcatheter Aortic Valve Replacemen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients suffering severe aortic stenosis and requiring pre-dilation during TAVR

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥18 years old;
  • Severe aortic stenosis verified by echocardiogram: mean transvalvular gradient≥40mmHg (1mmHg=0.133kPa), or peak aortic jet velocity≥4m/s, or aortic valve area (AVA) ≤ 1.0cm2 (or AVA index≤ 0.6cm2/m2);
  • Patients, who can understand the clinical investigation purpose, voluntary agree and sign the form, and willing to comply with relevant trial assessments and clinical follow up

Exclusion criteria

Exclusion Criteria:

  • Aortic valve anatomy or lesion unsuitable or not necessary for balloon pre-dilation during the TAVR procedure
  • TAVR procedure in trans-apical access
  • Pre-implanted mechanical or bioprosthetic valve at the aortic valve position
  • Acute myocardial infarction (MI) occurred in the last 30 days before the treatment;
  • LVOT obstruction;
  • Serious left ventricular dysfunction with (LVEF) \<20%
  • Echocardiographic evidence of intracardiac mass, thrombus or neoplasm;
  • Unable to receive anticoagulation or antiplatelet therapy;
  • Allergy to nitinol or sensitive contrast media;
  • Active bacterial endocarditis or other active infection may affect the procedure;
  • Aortic valve anatomy , lesion, or other situation unsuitable for the prosthesis valve implantation as assessed by the investigator team;
  • > 12 months;
  • vulnerable individuals who are unable to give / unable to fully understand all aspects of the investigation or Severe incapacitating Alzheimer's disease;
  • Patients who participated in other clinic trials of drugs or medical device before being enrolled for which the primary endpoint follow up duration has not been reached;
  • Investigators determined that patients have poor compliance and can't complete the study as required
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (actual)
Patient registry
No

Groups and cohorts

  • Alwide Plus

    Paitents perfomed TAVR and have Alwlide Plus Balloon Catheter pre-dilaton or post-dilation

06

What researchers measure

Primary outcomes

  1. Percentage of patients with TAVI device success at immediate post-procedure

    TAVI device success, defined as (meeting all the following criteria): Freedom from mortality; Successful access, delivery, deployment, implantation of the valve, and retrieval of the delivery system; Correct positioning of the prosthetic heart valve into the proper anatomical location; Intended performance of the valves (mean gradient \<20mmHg, or peak velocity \<3 m/s, and no severe aortic regurgitation or paravalvular leakage).

    Time frame: Immediate post-procedure

Secondary outcomes

  1. Percentage of patients with balloon pre-dilation success

    defined as successful access, delivery and dilation the aortic valve, and retrieval for the AlwideTM Plus balloon catheter

    Time frame: Immediate post-procedure

  2. Percentage of paitents with balloon post-dilation success

    defined as successful access, delivery and dilation the transcatheter aortic valve, and retrieval for the AlwideTM Plus balloon catheter

    Time frame: Immediate post-procedure

  3. Incidence of all-cause mortality, disabling and non-disabling stroke, life-threatening or disabling bleeding, major bleeding, acute kidney injury(AKIN≥2), major vascular complications and new permanent pacemaker implantation

    Definition following VARC-2 criteria

    Time frame: Immediate post-procedure and 30 days post-procedure

  4. Prosthetic valve performance-mean transvalular pressure gradient

    Prosthetic valve performance-mean pressure gradient(assessed by echocardiography), unit -mmHg

    Time frame: Immediate post-procedure and discharge(within 7 days post-procedure)

  5. Prosthetic valve performance-orifice area

    Prosthetic valve performance-orifice area(assessed by echocardiography), unit -cm2

    Time frame: Immediate post-procedure and discharge(within 7 days post-procedure)

  6. Prosthetic valve performance-valve regurgitation(intra- and para valvular leakage)

    Prosthetic valve performance-valve regurgitation(intra- and para valvular leakage), none/trace/mild/moderate/severe

    Time frame: Immediate post-procedure and discharge(within 7 days post-procedure)

07

Study locations

4 sites
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi, China
  • Yan'an Hospital of Kunming City
    Kunming, Yunnan, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Oct 2025, 9 months.

Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 9 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 26, 2025
StartActual
Jan 3, 2025
Primary completionActual
Oct 11, 2025
CompletionActual
Nov 4, 2025
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07304427
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Jan 3, 2025
Primary completion
Oct 11, 2025
Completion
Nov 4, 2025
Last update
Dec 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion